LLY
Eli Lilly and Company
LLY has the edge over UHS overall, supported by stronger fundamentals and stronger modeled upside.
UHS
Universal Health Services, Inc.
UHS offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
UHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
UHS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
UHS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.1x | $194 | — |
| Forward | 8.6x | $194 | — |
| Cheap | 9.7x | $231 | +19% |
| Fair | 12x | $296 | +53% |
| Expensive | 15x | $367 | +89% |
Historical ranges are pointers, not guarantees.
UHS has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over UHS on the outlook, with more favorable valuation and earnings expectations.
UHS Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect UHS's revenue to grow, but its profitability to weaken.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over UHS on earnings, with stronger typical year-over-year growth.
UHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.52 | -5.6% |
| Q3 2026 | $23.86 | +13% |
| Q2 2026 | $24.50 | +29% |
| Q1 2026 | $23.95 | +35% |
| Q4 2025 | $23.10 | +37% |
| Q3 2025 | $21.03 | +40% |
| Q2 2025 | $18.97 | +39% |
| Q1 2025 | $17.80 | +51% |
| Q4 2024 | $16.82 | +64% |
UHS's earnings per share have climbed steadily: $23.86 over the past year, up 13% from the year before, and higher year over year for 12 quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over UHS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over UHS on profitability, with a higher operating margin.
UHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.7B | +5.3% |
| Q2 2026 | $4.6B | +8.3% |
| Q1 2026 | $4.5B | +9.6% |
| Q4 2025 | $4.5B | +9.1% |
| Q3 2025 | $4.5B | +13% |
| Q2 2025 | $4.3B | +9.6% |
| Q1 2025 | $4.1B | +6.7% |
| Q4 2024 | $4.1B | +11% |
UHS's revenue has grown year over year every quarter since late 2020: $4.7B last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -2 points |
| Q2 2026 | 11% | -0.5 points |
| Q1 2026 | 11% | +0.1 points |
| Q4 2025 | 12% | 0 points |
| Q3 2025 | 12% | +1.9 points |
| Q2 2025 | 12% | +0.5 points |
| Q1 2025 | 11% | +1 points |
| Q4 2024 | 11% | +2.6 points |
UHS's operating margin was 9.6% last quarter, down 2 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over UHS on cash flow, with more consistent year-over-year improvement.
UHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $421.6M | +178% |
| Q2 2026 | $215.7M | -24% |
| Q1 2026 | $184.5M | +52% |
| Q4 2025 | $293.5M | -29% |
| Q3 2025 | $151.8M | +78% |
| Q2 2025 | $283M | -35% |
| Q1 2025 | $121M | -36% |
| Q4 2024 | $412.5M | +68% |
UHS still generates free cash flow, though less than at its 2020 peak: $1.1B over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
UHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -765K shares |
| 1 year | -7.1% | -4.5M shares |
| 3 years | -15% | -10.5M shares |
| 5 years | -29% | -24.5M shares |
| Available history | -34% | -29.9M shares |
UHS has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $245.3M |
| Q2 2026 | $320.8M |
| Q1 2026 | $163.8M |
| Q4 2025 | $352M |
| Q3 2025 | $237.4M |
| Q2 2025 | $155.2M |
| Q1 2025 | $223.4M |
| Q4 2024 | $250.2M |
UHS spent $1.1B buying back its own shares over the past year, up 25% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over UHS on leverage, with a lower net debt burden relative to earnings.
UHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
UHS's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
UHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.4 | Neutral |
| Stochastic | 71.1 | Neutral |
UHS's weekly RSI is 60 (neutral) and its Stochastic is 71 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
UHS PE vs Healthcare Sector
| Metric | UHS | Sector median | Relative |
|---|---|---|---|
| PE | 8.1x | 26x | 69% below |
| PE % | 9 | 29 | 20 pts below |
UHS has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
UHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.7 | 5.5% above |
| 20 week MA | $173.6 | 12% above |
| 50 week MA | $183.2 | 5.8% above |
| 100 week MA | $185.2 | 4.7% above |
| 200 week MA | $174.6 | 11% above |
UHS is in an uptrend: it's above all five of its weekly moving averages, and 11% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over UHS on returns for 2026, with the stronger performance.
UHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143.4 | $136.9 | -4.5% |
| 2021 | $136.9 | $128.1 | -6.4% |
| 2022 | $128.1 | $140.8 | +9.9% |
| 2023 | $140.8 | $152.4 | +8.3% |
| 2024 | $152.4 | $180.5 | +18% |
| 2025 | $180.5 | $227.6 | +26% |
| 2026 YTD | $227.6 | $193.8 | -15% |
UHS has finished higher in four of the last six years. It's down 15% so far in 2026.